{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:19:35Z","timestamp":1791425975483,"version":"4.3.3"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Treatment with the nucleoside analog T-1106 was previously shown to be effective in a hamster model of yellow fever virus (YFV) disease, even though it had only slight activity in cell culture. In the study described in this report, the activity of T-705, a chemically related compound currently undergoing clinical trials for the treatment of influenza (FDANews 4:1, 2007), was tested against YFV in cell culture and in the hamster model. The antiviral efficacy of T-705 in cell culture occurred at a concentration of 330 \u03bcM, which was more than threefold lower than the concentration at which T-1106 had antiviral efficacy, as determined by a virus yield reduction assay and confirmed by a luciferase-based ATP detection assay. Time-of-addition studies revealed that addition of T-705, T-1106, or ribavirin at 0, 4, 8, or 12 h after virus challenge was effective in inhibiting virus in Vero cells, suggesting that these three agents have similar mechanisms of action in cell culture. Because of its more potent activity in cell culture, it was anticipated that T-705 treatment of hamsters infected with YFV would result in protection from disease. Significant improvements in survival and disease parameters were seen in infected animals when T-705 was administered orally at a dose of 200 or 400 mg\/kg of body weight per day when it was given twice a day for 8 days. Significant improvements were also observed with a dose of 400 mg\/kg\/day when treatment initiation was delayed as late as 3 days after virus inoculation. Although the dose of T-705 required for efficacy in hamsters is higher than that of T-1106 required for efficacy, T-705 treatment is effective in significantly improving disease parameters in YFV-infected hamsters, which may indicate its potential utility in the treatment of YFV disease in humans.<\/jats:p>","DOI":"10.1128\/aac.01074-08","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T00:26:04Z","timestamp":1225153564000},"page":"202-209","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":141,"title":["Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106"],"prefix":"10.1128","volume":"53","author":[{"given":"Justin G.","family":"Julander","sequence":"first","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"Shafer","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald F.","family":"Smee","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Morrey","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Toyama Chemical Company, Ltd., 3-2-5 Nishishinjuku, Shinjuku-ku, Tokyo 187-0023, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.12.001"},{"key":"e_1_3_2_3_2","first-page":"421","volume":"80","year":"1960","unstructured":"Bearcroft, W. G. 1960. Electron-microscope studies on the liver cells of yellow-fever-infected rhesus monkeys. J. Pathol. Bacteriol.80:421-426.","journal-title":"J. Pathol. Bacteriol."},{"key":"e_1_3_2_4_2","first-page":"989","volume":"51","year":"2002","unstructured":"Centers for Disease Control and Prevention. 2002. Adverse events associated with 17D-derived yellow fever vaccination\u2014United States, 2001-2002. MMWR Morb. Mortal. Wkly. Rep.51:989-993.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_5_2","first-page":"1","volume":"4","year":"2007","unstructured":"FDANews. 2007. Toyama starts U.S. trials of polymerase inhibitor. RxTrials Institute drug pipeline alert. FDANews4:1.","journal-title":"FDANews"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.981-986.2005"},{"key":"e_1_3_2_8_2","first-page":"199","year":"2004","unstructured":"Furuta, Y., K. Takahashi, and M. Maekawa. 2004. T-1106, a novel pyrazine nucleoside, hepatitis C virus polymerase inhibitor, p. 199-200. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-07"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.3.512"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01494-06"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.08.008"},{"key":"e_1_3_2_13_2","first-page":"131","volume":"85","year":"2002","unstructured":"Kengsakul, K., K. Sathirapongsasuti, and S. Punyagupta. 2002. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J. Med. Assoc. Thai.85:131-134.","journal-title":"J. Med. Assoc. Thai."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","volume":"23","year":"2005","unstructured":"Khromava, A. Y., R. B. Eidex, L. H. Weld, K. S. Kohl, R. D. Bradshaw, R. T. Chen, and M. S. Cetron. 2005. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine23:3256-3263.","journal-title":"Vaccine"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/516111"},{"key":"e_1_3_2_16_2","first-page":"501","volume":"45","year":"1964","unstructured":"McGavran, M. H., and J. D. White. 1964. Electron microscopic and immunofluorescent observations on monkey liver and tissue culture cells infected with the asibi strain of yellow fever virus. Am. J. Pathol.45:501-517.","journal-title":"Am. J. Pathol."},{"key":"e_1_3_2_17_2","first-page":"341","volume":"99","year":"2006","unstructured":"Monath, T. P. 2006. Yellow fever as an endemic\/epidemic disease and priorities for vaccination. Bull. Soc. Pathol. Exot.99:341-347.","journal-title":"Bull. Soc. Pathol. Exot."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1981.30.431"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.07.009"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2004.71.306"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2006.74.1084"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01051-06"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020301400502"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/320199"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/10408360490497474"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05326-0"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/320200"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01074-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01074-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:45:46Z","timestamp":1645472746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01074-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1128\/AAC.01074-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01074-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"2008-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-10-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}